Eterna Therapeutics
ERNA
49 hedge funds and large institutions have $38.4M invested in Eterna Therapeutics in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 8 closing their positions.
510% more call options, than puts
Call options by funds: $299K | Put options by funds: $49K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
4% more funds holding
Funds holding: 47 → 49 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
26% less capital invested
Capital invested by funds: $52.1M → $38.4M (-$13.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$13.9M |
| 2 |
Renaissance Technologies
New York
|
+$721K |
| 3 |
BlackRock
New York
|
+$607K |
| 4 |
JP Morgan Chase
New York
|
+$569K |
| 5 |
Morgan Stanley
New York
|
+$455K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$474K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$304K |
| 3 |
Two Sigma Investments
New York
|
-$304K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$190K |
| 5 |
Two Sigma Advisers
New York
|
-$94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $5K | -$19K | -1 | Closed |
|
|
CG
52
Cutler Group
San Francisco,
California
| $5K | – | – | – |
|
53
Fidelity Investments
Boston,
Massachusetts
| $5K | – | – | – |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | -$19K | -1 | Closed |
|
|
AIP
55
Ameritas Investment Partners
Lincoln,
Nebraska
| $4K | – | – | – |
|
56
Group One Trading
Chicago,
Illinois
| $4K | – | – | – |
|
|
CHA
57
Carmichael Hill & Associates
Gaithersburg,
Maryland
| $3K | – | – | – |
|
|
MA
58
Montag & Associates
Atlanta,
Georgia
| $3K | – | – | – |
|
|
59
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$304K | -10 | Closed |
|
60
Millennium Management
New York
| – | -$85K | -3 | Closed |
|
|
61
Two Sigma Advisers
New York
| – | -$94K | -3 | Closed |
|
|
JF
62
Jump Financial
Chicago,
Illinois
| – | -$65K | -2 | Closed |
|
63
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$56 | -2 | Closed |
|
64
Simplex Trading
Chicago,
Illinois
| – | -$19K | -1 | Closed |
|
ERNA Hedge Fund Activity: Q1 2022 in Review
49 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2022, worth a combined $38.4M — down 26% from $52.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ERNA positions and 8 closed out — a net gain of 2 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $13.9M. The largest seller was Raymond James & Associates, cutting an estimated $474K.
- 49 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2022, up from 47 in Q4 2021.
- Funds reported $38.4M of Eterna Therapeutics stock for Q1 2022, down 26% quarter-over-quarter.
- 10 funds opened new Eterna Therapeutics positions in Q1 2022 and 8 closed out, a net change of +2 holders.
- The largest Eterna Therapeutics buyer in Q1 2022 was Armistice Capital, an estimated $13.9M added.
- The largest Eterna Therapeutics seller in Q1 2022 was Raymond James & Associates, an estimated $474K sold.
Based on aggregated 13F filings for Q1 2022.